Biotech Is the Cheapest Since 2011: 4 Top Stocks to Buy Now
Jefferies has four top biotech picks for 2016 that all have substantial upside and may provide investors with solid alpha for 2016.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 228
Short Sellers Become More Selective on Major Pharma
The January 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
Short Sellers Increase Bets in Major Biotechs
Short interest increased in most of these selected biotech stocks for the most recent settlement date.
Opposing Views on Medivation News and Xtandi
Medivation, Inc. (NASDAQ: MDVN) was not having a great day on Wednesday. Its shares were seen down 5% or so at $33.10 shortly before the close. News was out on Tuesday signaling that the…
Anthem Shows Health Care Costs Eating Into Profits
Anthem is the latest health insurance provider to have some concerns around its earnings report.
Regeneron Downgrade Highlights at Least Some Risks
Regeneron Pharmaceuticals seems to have held up rather well against an analyst downgrade on Wednesday.
How Anthem Fell Short on Earnings and Membership
Anthem released a disappointing fourth-quarter earnings report before the markets opened Wednesday.
How Biogen Won at Earnings in Q4
Biogen reported better-than-expected fourth-quarter financial results before the markets opened on Wednesday.
What to Expect From Biogen Earnings
Biogen is set to report its fourth-quarter financial results before the markets open Wednesday.
Centene Data Debacle Affects 950,000 Customers
Centene said on Monday that it is conducting an "ongoing comprehensive internal search for six hard drives" that failed to turn up during an inventory count of its IT assets.
Tactile Systems Files for IPO
Tactile Systems Technology has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Relypsa Soars on Positive Phase 1 Results
Relypsa rose early in Monday’s session as the result of positive results from its Phase 1 in vivo studies evaluating the interactions between Veltassa (patiromer) and other drugs.
Johnson & Johnson Kicks Off 2016 With Solid Earnings and Guidance
Johnson & Johnson reported its fourth-quarter financial results before the markets opened on Tuesday.
What to Look for in Johnson & Johnson Earnings
Johnson & Johnson is set to release its fourth-quarter financial results before the markets open Tuesday.
Could This Merck Deal Be the Turning Point for Affimed?
Affimed shares rose on Monday following the announcement of a collaboration in immuno-oncology with biotech giant Merck.